Kronos Bio Analyst Ratings
Kronos Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 525% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 04/17/2023 | 594.44% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 11/18/2022 | 594.44% | HC Wainwright & Co. | $36 → $10 | Maintains | Buy |
| 11/10/2022 | 872.22% | Goldman Sachs | $25 → $14 | Maintains | Buy |
| 11/09/2022 | 386.11% | Piper Sandler | $13 → $7 | Maintains | Overweight |
| 09/14/2022 | 733.33% | Berenberg | → $12 | Initiates Coverage On | → Buy |
| 05/24/2022 | 1497.22% | Goldman Sachs | $35 → $23 | Maintains | Buy |
| 05/23/2022 | 802.78% | Piper Sandler | $30 → $13 | Maintains | Overweight |
| 02/28/2022 | 1983.33% | Piper Sandler | $50 → $30 | Maintains | Overweight |
| 11/10/2021 | 2400% | HC Wainwright & Co. | $35 → $36 | Maintains | Buy |
| 06/24/2021 | 2330.56% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 11/03/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/03/2020 | 3025% | Goldman Sachs | → $45 | Initiates Coverage On | → Buy |
| 11/03/2020 | 3372.22% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月21日 | 525% | HC Wainwright公司 | $10→$9 | 维护 | 买 |
| 04/17/2023 | 594.44% | HC Wainwright公司 | →$10 | 重申 | →购买 |
| 2022年11月18日 | 594.44% | HC Wainwright公司 | $36→$10 | 维护 | 买 |
| 2022年11月10日 | 872.22% | 高盛 | $25→$14 | 维护 | 买 |
| 11/09/2022 | 386.11% | 派珀·桑德勒 | $13→$7 | 维护 | 超重 |
| 09/14/2022 | 733.33% | 贝伦伯格 | →$12 | 开始承保 | →购买 |
| 2022年05月24日 | 1497.22% | 高盛 | $35→$23 | 维护 | 买 |
| 2022年05月23日 | 802.78% | 派珀·桑德勒 | $30→$13 | 维护 | 超重 |
| 02/28/2022 | 1983.33% | 派珀·桑德勒 | $50→$30 | 维护 | 超重 |
| 2021年11月10日 | 2400% | HC Wainwright公司 | $35→$36 | 维护 | 买 |
| 06/24/2021 | 2330.56% | HC Wainwright公司 | →$35 | 开始承保 | →购买 |
| 11/03/2020 | - | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 11/03/2020 | 3025% | 高盛 | →$45 | 开始承保 | →购买 |
| 11/03/2020 | 3372.22% | 派珀·桑德勒 | →$50 | 开始承保 | →超重 |
What is the target price for Kronos Bio (KRON)?
Kronos Bio(KRON)的目标价是多少？
The latest price target for Kronos Bio (NASDAQ: KRON) was reported by HC Wainwright & Co. on August 21, 2023. The analyst firm set a price target for $9.00 expecting KRON to rise to within 12 months (a possible 525.00% upside). 6 analyst firms have reported ratings in the last year.
克罗诺斯生物公司(纳斯达克代码：KRON)的最新目标价是由HC Wainwright&Co.于2023年8月21日报道的。这家分析公司将目标价定为9美元，预计KRON将在12个月内上涨至(可能上涨525.00%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Kronos Bio (KRON)?
Kronos Bio(KRON)的最新分析师评级是多少？
The latest analyst rating for Kronos Bio (NASDAQ: KRON) was provided by HC Wainwright & Co., and Kronos Bio maintained their buy rating.
分析师对克罗诺斯生物公司(纳斯达克代码：KRON)的最新评级由HC Wainwright&Co.提供，克罗诺斯生物公司维持其买入评级。
When is the next analyst rating going to be posted or updated for Kronos Bio (KRON)?
Kronos Bio(KRON)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kronos Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kronos Bio was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Kronos Bio的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Kronos Bio的上一次评级是在2023年8月21日提交的，所以你应该预计下一次评级将在2024年8月21日左右的某个时候提供。
Is the Analyst Rating Kronos Bio (KRON) correct?
分析师对Kronos Bio(KRON)的评级正确吗？
While ratings are subjective and will change, the latest Kronos Bio (KRON) rating was a maintained with a price target of $10.00 to $9.00. The current price Kronos Bio (KRON) is trading at is $1.44, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Kronos Bio(KRON)评级维持不变，目标价在10.00美元至9.00美元之间。Kronos Bio(KRON)目前的交易价格为1.44美元，超出了分析师的预测区间。